Chunghwa Chemical Synthesis & Biotech Co., Ltd. (TPE:1762)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
26.90
+1.15 (4.47%)
At close: Feb 11, 2026
Market Cap2.07B -19.6%
Revenue (ttm)977.79M -35.5%
Net Income-102.95M
EPS-2.61
Shares Out76.92M
PE Ration/a
Forward PEn/a
Dividend0.19 (0.74%)
Ex-Dividend DateJul 24, 2025
Volume175,024
Average Volume127,089
Open26.30
Previous Close25.75
Day's Range25.80 - 27.25
52-Week Range23.50 - 36.35
Beta0.51
RSI61.85
Earnings DateMar 20, 2026

About TPE:1762

Chunghwa Chemical Synthesis & Biotech Co., Ltd. engages in the research, development, manufacturing, and sale of active pharmaceutical ingredients in Taiwan, the United States, India, Greece, Croatia, Japan, and internationally. The company offers antifungal, immunosuppressant, oncology, cardiovascular, peptide drug, immunomodulating agents, statin, muscle relaxant, ACE inhibitor with complete DMF or COS, and other API products. It also provides specialty API immunosuppressants, including mycophenolate mofetil, rapamycin, and tacrolimus; deriva... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1964
Employees 198
Stock Exchange Taiwan Stock Exchange
Ticker Symbol 1762
Full Company Profile

Financial Performance

In 2024, TPE:1762's revenue was 1.35 billion, a decrease of -35.42% compared to the previous year's 2.09 billion. Earnings were 53.03 million, a decrease of -79.98%.

Financial Statements